Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.
Reservation Policy & Attendance Limit: This event has an attendance limit of 300 people and seats will be reserved on a first-come, first-served basis. Please be sure to register as soon as possible to reserve your seat and ensure your attendance.
*We strive to be inclusive. All are welcome to attend!